$1,318.00
This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Medical management
8 Medical procedures and surgery
9 Cardiac rehabilitation
10 EPIDEMIOLOGY
16 MARKETED DRUGS
18 PIPELINE DRUGS
22 KEY UPCOMING EVENTS
23 PROBABILITY OF SUCCESS
24 REVENUE OPPORTUNITY
25 CLINICAL TRIAL LANDSCAPE
26 Sponsors by status
27 Sponsors by phase
29 BIBLIOGRAPHY
31 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of coronary artery disease, 2020–29
15 Figure 2: Trends in incident cases of acute coronary syndrome, 2020–29
18 Figure 3: Overview of pipeline drugs for coronary artery disease in the US
18 Figure 4: Pipeline drugs for coronary artery disease, by company
19 Figure 5: Pipeline drugs for coronary artery disease, by drug type
19 Figure 6: Pipeline drugs for coronary artery disease, by classification
22 Figure 7: Key upcoming events in coronary artery disease
23 Figure 8: Probability of success in the cardiovascular pipeline
25 Figure 9: Clinical trials in coronary artery disease
25 Figure 10: Top 10 drugs for clinical trials in coronary artery disease
26 Figure 11: Top 10 companies for clinical trials in coronary artery disease
26 Figure 12: Trial locations in coronary artery disease
27 Figure 13: Coronary artery disease trials status
28 Figure 14: Coronary artery disease trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of coronary artery disease, 2020–29
13 Table 2: Prevalent cases of coronary artery disease in select regions, by gender, 2020
14 Table 3: Incident cases of acute coronary syndrome, 2020–29
17 Table 4: Marketed drugs for coronary artery disease
20 Table 5: Pipeline drugs for coronary artery disease in the US
24 Table 6: Historical global sales, by drug ($m), 2017–21
24 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!